Cumberland Pharma wants a new product this year

Cumberland Pharmaceuticals (Ticker: CPIX) wants to add a new product in 2011. On the Nashville company's fourth-quarter earnings call Tuesday, CEO A.J. Kazimi said the company is looking for a candidate in the late-stage of development so it can be launched quickly. Cumberland Pharma is looking both externally and internally — at its Cumberland Emerging Technologies subsidiary — for the next addition to its portfolio.

"Our strong financial profile puts us in an ideal position to make such a move in 2011," Kazimi said.

Mar 9, 2011 7:28 AM

New Americas R&D chief for Nissan

Nissan Americas says Carla Bailo, who joined the automaker in 1999 and now is general manager of a division in Japan, will take over the leadership of its engineering and development operations come April 1. The job is based in Michigan.
Feb 18, 2011 9:59 AM

Biotech firm gets St. Jude licensing deal

Nashville biotechnology firm Insight Genetics has inked a license agreement with St. Jude Children's Research Hospital. The deal, for rights to mutations in a specific cancer-causing gene, should help Insight Genetics create a diagnostic test to help doctors monitor and treat cancer patients.
"The test we are developing from discoveries made at St. Jude will yield great improvements in the care of patients with a variety of cancers caused by ALK, including lung cancers, lymphomas, certain sarcomas and other malignancies," said Dr. Josh Nickols, Chief Technology Officer and VP of Research and Development at Insight Genetics. "We believe the test will be able to provide clinicians with the ability to make rapid, informed decisions about therapy selection for their patients during the course of treatment with ALK inhibitors."
Dec 14, 2010 1:02 PM

Tennessee Biotech Assn. rebrands

The Tennessee Biotechnology Association has changed its name to Life Sciences Tennessee. The switch is designed to reflect the organization's broader focus on industries including biotechnology, pharmaceuticals, biomedical technologies and devices, biofuels, food processing and supporting research and development organizations.
“The goal of our organization is to create investment and partnering opportunities, help attract and retain the best talent and provide networking and educational opportunities within the life science industry in Tennessee. Therefore, casting a broader net, both in name and in spirit, and being the organization that advances all the Life Sciences makes sense,” said Life Science Tennessee board member Joe Cook Jr. “Tennessee is already doing amazing work in the life sciences, and the potential to grow this industry in our state and bring with it the economic opportunity, the high-paying jobs, the innovations and the course-altering discoveries is an exciting proposition.”
The organization will make it's official debut at its annual meeting on Nov. 12 at the Renaissance Hotel. Click here for information on the event.
Oct 22, 2010 1:21 PM

BioMimetic shares open lower on offering news

Despite a broader market rebound Tuesday, shares of BioMimetic Therapeutics Inc. (Ticker: BMTI) opened about $1 lower — down about 9 percent — on heavy trading volume following news that the company will offer 5 million shares of its common stock to help pay for product development and commercialization efforts. The Dow Jones Industrial Average and the Nasdaq Composite each rose about 1 percent on a positive start to corporate earnings season.
Jul 13, 2010 9:26 AM

PureSafety and eMids renew partnership

PureSafety and eMids Technologies have renewed their partnership and contract for its product development center, the companies announced Friday. In the "Extended Center Model," a dedicated eMids team works exclusively on research and development, quality assurance and other product engineering projects for Franklin-based PureSafety.
Feb 15, 2010 7:47 AM

TSU looks to shape research consortium

Milt Capps has the lowdown on efforts to form the Capital City Research Consortium, a group that would improve the region's technology transfer system.
Feb 2, 2010 8:19 AM

Stimulus grants for Vandy cancer researcher

Vanderbilt University Medical Center cancer investigator H. Charles Manning has received two grants, totaling $1.6 million, from the National Cancer Institute to study imaging techniques in colorectal cancer. The grants are part of the federal government's stimulus package funded through the American Recovery and Reinvestment Act.
“The promise of molecular imaging is to rapidly and noninvasively interrogate tissues of interest without tissue sampling, such as biopsy,” said Manning. “Molecular imaging biomarkers ... may enable us to determine whether a drug is working as early as a few hours after administration as well as predict whether patients will continue to respond over time. This information could spare patients the expense and potential side effects of ineffective therapies.”
Jan 29, 2010 7:22 AM

Canadian OK for BioMimetic

Canada's health regulators have given BioMimetic Therapeutics the go-ahead to market its Augment Bone Graft product via an Ontario-based distributor. It'll be for sale in time for Christmas.
Nov 4, 2009 7:27 AM

BioMimetic does its paperwork

The Franklin-based maker of regnerative tissues has submitted several parts of its application to bring Augment Bone Graft to market. Investors are rewarding that by pushing up its shares (Ticker: BMTI) by 7 percent in pre-market action this morning.
Jun 18, 2009 8:03 AM